Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 4, 2025
Reporting Period: Event-based report regarding capital raising activities.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The report focuses exclusively on capital structure changes related to an equity offering.
| Metric | Value |
|---|---|
| Previous Maximum Offering Amount (Sales Agreement) | $5,100,000 |
| New Maximum Offering Amount (Sales Agreement) | $11,200,000 |
| Amount of New Prospectus Supplement | $6,100,000 |
| Shares Sold Under Agreement Prior to Date | Approximately $5,000,000 (aggregate sales price) |
Material Changes
- Expansion of Equity Facility: On February 4, 2025, the Company increased the maximum aggregate offering amount under its At The Market Offering Agreement (Sales Agreement) with Ladenburg Thalmann & Co. Inc. from $5,100,000 to $11,200,000.
- Prospectus Supplement Filed: A prospectus supplement was filed to cover an additional $6,100,000 of common stock issuable under the Sales Agreement.
- Utilization of Prior Facility: Prior to this increase, the Company had already sold shares with an aggregate sales price of approximately $5,000,000 under the original agreement.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates the Company is actively managing its liquidity by expanding its ability to raise capital through the existing Sales Agreement. No specific operational guidance or future financial outlook is provided in this document.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard implications of issuing additional equity, which may result in dilution to existing shareholders. The filing confirms the Company is an emerging growth company.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of the additional $6,100,000 offering capacity.
- Review the full text of the Sales Agreement with Ladenburg Thalmann & Co. Inc. to understand pricing mechanisms and termination rights.
- Confirm the Company's current cash position and burn rate to assess the necessity of this capital raise.
- Check for any subsequent filings regarding the actual issuance of shares under the new $6,100,000 supplement.